Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > 2.39 ASK

<< Previous

Bullboard Posts

Next >>

Comment by Bertie20on Oct 12, 2021 10:40am

127 Views

Post# 33997094

RE:RE:RE:RE:RE:RE:RE:2.39 ASK

This is my last comment on the matter. Look up bid:ask price. You typically don't pay the share price--you pay the bid price to buy (usually higher than the stated share price), and sell at the ask price (lower than the share price). The highest bid price I saw was C$2.24, but someone mentioned as high as C$2.39 earlier. This is all very basic stuff.
All the best

<< Previous

Bullboard Posts

Next >>

BMO evolves InvestorLine with enhanced tools for options trading